Facet Life Sciences, a leader in regulatory strategy and drug development services, announced a strategic partnership with XCancer®, a global leader in theranostic clinical research, to accelerate the development and approval of next-generation radiopharmaceutical therapies in oncology.

Facet is now featured on TheranosticTrials.Org®, XCancer's premier collaboration platform that connects researchers, clinicians, sponsors, and advocates to expand awareness, share expertise, and promote global access to cancer innovation.

The collaboration combines Facet's deep regulatory and development expertise in diagnostic and therapeutic radiopharmaceuticals—including U.S. regulatory planning, FDA submissions, and oncology program strategy—with XCancer's expansive theranostic clinical trial network and infrastructure. Together, the organizations will streamline the path for sponsors to bring precision diagnostic and therapeutic radiopharmaceuticals to patients more efficiently.

"At Facet, our mission has always included bringing diagnostic and radiopharmaceutical therapies to patients faster and more efficiently," said Dr. Lisa Jenkins VanLuvanee, COO of Facet Life Sciences. "By partnering with XCancer and TheranosticTrials.Org, we are combining our regulatory and oncology expertise with their groundbreaking clinical research capabilities. This collaboration positions us to accelerate the advancement of theranostic therapies and expand patient access to precision medicine."

"Facet's proven regulatory and strategic development expertise complements XCancer's mission perfectly," said Dr. Luke Nordquist, CEO of XCancer and Founder of TheranosticTrials.Org. "Together, we are building an ecosystem that removes barriers for Sponsors, accelerates clinical trial activation, and brings life-changing radiopharmaceutical therapies to patients who need them most. This partnership exemplifies what theranostics is all about—uniting diagnostics and therapeutics through collaboration to deliver truly personalized cancer care."

Combining diagnostic imaging with targeted therapy represents one of the most promising frontiers in oncology. The Facet–XCancer partnership will simplify the complex development and regulatory pathways that often delay innovative therapies from reaching patients in need.